11 – 20 of 327
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Recombinant FVIII replacement products for haemophilia A : An updated valuation by indirect comparison measuring area under the curve
- Contribution to journal › Debate/Note/Editorial
-
Mark
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
- Contribution to journal › Letter
-
Mark
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
- Contribution to journal › Article
-
Mark
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
(2024) In Haemophilia
- Contribution to journal › Article
-
Mark
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
(2024) In Haemophilia
- Contribution to journal › Article
- 2023
-
Mark
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
- Contribution to journal › Article
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
- Contribution to journal › Scientific review
-
Mark
Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging
- Contribution to journal › Article
